COMMUNIQUÉS West-GlobeNewswire

Aptose Announces Results from Annual and Special Meeting of Shareholders
27/05/2025
SAN DIEGO and TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple [...]
CARBIOS signe ses premiers contrats de vente de PET biorecyclé avec deux leaders mondiaux de la cosmétique
27/05/2025
CARBIOS a signé deux contrats commerciaux pluriannuels de PET biorecyclé issu de l’usine de Longlaville, avec L’ORÉAL et L’Occitane en Provence et réalise une avancée dans l’exécution de sa stratégie pour sa future [...]
CARBIOS signs its first biorecycled PET sales contracts with two global cosmetics leaders
27/05/2025
CARBIOS has signed two multi-year commercial contracts for biorecycled PET from its Longlaville plant, with L'ORÉAL and L'Occitane en Provence, and has moved forward with the execution of this future plant’s strategy [...]
Nexzen Extracts Emerges as a Premium Name in Hemp-Derived Wellness Products
27/05/2025
Nexzen Extracts, a rising brand in the hemp and cannabis wellness space, has officially announced its expansion into the national market with a product line focused on purity, potency, and plant-based innovation [...]
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
27/05/2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 [...]
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees
27/05/2025
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of [...]
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
27/05/2025
Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology [...]
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
27/05/2025
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical [...]
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
27/05/2025
Vadadustat clinical data on display for nephrologists and healthcare providers CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose [...]
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
27/05/2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic [...]
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
27/05/2025
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a [...]
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
27/05/2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing [...]
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
27/05/2025
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
27/05/2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal [...]
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
27/05/2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the [...]
Strongline returns to market, signs deal with QLog to ensure leading staff duress offering is available to health systems around the country
27/05/2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Commure announced today a strategic partnership and licensing agreement with QLog, a leading Israeli innovator in real-time location systems (RTLS) and Bluetooth Low [...]
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
27/05/2025
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus [...]
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
27/05/2025
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/ [...]
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
27/05/2025
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. ( the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to [...]

Pages